Tonix Pharmaceuticals Holding (TNXP) Research & Development (2011 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Research & Development of $18.2 million for Q1 2026, up 144.93% year-over-year from $7.4 million in Q1 2025, and up 7.51% quarter-over-quarter from $16.9 million in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Research & Development (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Research & Development history runs 16 years deep, the most recent figure standing at $18.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 144.93% year-over-year to $18.2 million; the TTM figure through Mar 2026 stood at $55.3 million (up 59.97% YoY), while the FY2025 annual figure was $44.5 million, up 11.29% from the prior year.
- Research & Development for Q1 2026 stood at $18.2 million, up from $16.9 million in the prior quarter.
- The five-year high for Research & Development was $26.5 million in Q1 2023, with the low at $7.4 million in Q1 2025.
- The 5-year median for Research & Development is $16.9 million (2025), against an average of $16.0 million.
- The sharpest annual moves came in 2024 and 2026: Research & Development slumped 56.7% in 2024, then jumped 144.93% in 2026.
- Tonix Pharmaceuticals Holding's Research & Development stood at $24.7 million in 2022, then slumped by 30.62% to $17.1 million in 2023, then sank by 51.54% to $8.3 million in 2024, then jumped by 104.18% to $16.9 million in 2025, then climbed by 7.51% to $18.2 million in 2026.
- Business Quant data shows TNXP's Research & Development at $18.2 million in Q1 2026, $16.9 million in Q4 2025, and $9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | 19.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.42 Mn |
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 16.94 Mn |
| Sep 30, 2025 | 9.29 Mn |
| Jun 30, 2025 | 10.82 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Dec 31, 2024 | 8.30 Mn |
| Sep 30, 2024 | 9.11 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 12.86 Mn |
| Dec 31, 2023 | 17.12 Mn |
| Sep 30, 2023 | 21.05 Mn |
| Jun 30, 2023 | 21.98 Mn |
| Mar 31, 2023 | 26.51 Mn |
| Dec 31, 2022 | 24.67 Mn |
| Sep 30, 2022 | 22.20 Mn |
| Jun 30, 2022 | 16.58 Mn |
| Mar 31, 2022 | 18.42 Mn |
| Dec 31, 2021 | 22.30 Mn |
| Sep 30, 2021 | 13.08 Mn |